Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will release its second quarter 2021 financial results on September 8, 2021, followed by a conference call at 8:30 a.m. EDT. The call aims to discuss the financial results and recent corporate developments. Interested parties can access the call via phone or webcast, with details provided for both U.S. and international callers. Affimed focuses on immuno-oncology, leveraging its proprietary ROCK® platform to develop targeted treatments against various tumors. A replay of the call will be available for 30 days post-event.

Positive

• The upcoming conference call may provide transparency on financial results and corporate developments, which can positively influence investor confidence.

Negative

• None.

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6156773 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed N.V. release its second quarter 2021 results?

Affimed N.V. will release its second quarter 2021 results on September 8, 2021.

What time is the Affimed N.V. conference call regarding their financial results?

The conference call will take place at 8:30 a.m. EDT on September 8, 2021.

How can I access the Affimed N.V. conference call?

You can access the conference call via phone by dialing +1 (409) 220-9054 for U.S. callers or +44 (0) 8000 323836 for international callers, or through the live audio webcast on their website.

What is the significance of the ROCK® platform mentioned in Affimed's press release?

The ROCK® platform is used by Affimed to develop tumor-targeted therapies aimed at recognizing and destroying various tumors, indicating their innovative approach in cancer treatment.